The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes

  • Lee, Jin-Woo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Lee, Chang-Hoon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Kim, Deog-Kyeom (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Yoon, Ho-Il (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Jae-Yeol (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Lee, Sang-Min (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Yang, Seok-Chul (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Lee, Jae-Ho (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Yoo, Chul-Gyu (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Lee, Choon-Taek (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Chung, Hee-Soon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Kim, Young-Whan (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Han, Sung-Koo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine) ;
  • Yim, Jae-Joon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine)
  • Published : 2011.06.01
⟨ Previous Next ⟩

Abstract

Background/Aims: To compare the effect of levofloxacin and moxifloxacin on treatment outcomes among patients with multidrug-resistant tuberculosis (MDR-TB). Methods: A retrospective analysis of 171 patients with MDR-TB receiving either levofloxacin or moxifloxacin was performed. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). Results: The median age of the patients was 42.0 years. Approximately 56% of the patients were male. Seventeen patients had extensively drug-resistant tuberculosis, and 20 had a surgical resection. A total of 123 patients (71.9%) received levofloxacin for a median 594 days, and 48 patients (28.1%) received moxifloxacin for a median 673 days. Other baseline demographic, clinical, and radiographic characteristics were similar between the two groups. The moxifloxacin group had a significantly higher number of resistant drugs (p < 0.001) and a higher incidence of resistance to ofloxacin (p = 0.005) in the drug sensitivity test. The treatment success rate was 78.9% in the levofloxacin group and 83.3% in the moxifloxacin group (p = 0.42). Adverse reactions occurred at similar rates in the groups (p = 0.44). Patients in the moxifloxacin group were not more likely to have treatment success than those in the levofloxacin group (adjusted odds ratio, 0.76; 95% confidence interval, 0.24 to 2.43; p = 0.65). Conclusions: Both levofloxacin and moxifloxacin showed equivalent efficacy for treating MDR-TB.

Keywords

References

  1. World Health Organization. Multidrug and extensively drug-resistant tuberculosis: 2010 global report on surveillance and response. Geneva: World Health Organization, 2010.
  2. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18. https://doi.org/10.2165/00003495-200161010-00002
  3. van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53:849-862. https://doi.org/10.1128/AAC.00749-08
  4. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-2099. https://doi.org/10.2165/00003495-200767140-00007
  5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008.
  6. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-442. https://doi.org/10.1016/S1473-3099(03)00671-6
  7. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-782. https://doi.org/10.1128/AAC.48.3.780-782.2004
  8. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1999;58 Suppl 2:19-22.
  9. Rastogi N, Goh KS, Bryskier A, Devallois A. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:1610-1616.
  10. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003;124:1476-1481. https://doi.org/10.1378/chest.124.4.1476
  11. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744-751. https://doi.org/10.1378/chest.117.3.744
  12. Hwang SS, Kim HR, Kim HJ, et al. Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J 2009;33:581-585. https://doi.org/10.1183/09031936.00099608
  13. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patient s with multidrug-resistant tuberculosis. Clin Infect Dis 2007;45:1290-1295. https://doi.org/10.1086/522537
  14. Kim DK, Park GM, Hwang YI, et al. Microarray analysis of gene expression associated with extrapulmonary dissemination of tuberculosis. Respirology 2006;11:557-565. https://doi.org/10.1111/j.1440-1843.2006.00896.x
  15. Kim HJ, Kang CH, Kim YT, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006;28:576-580. https://doi.org/10.1183/09031936.06.00023006
  16. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-645.
  17. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005;365:318-326.
  18. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229-1235. https://doi.org/10.1001/jama.1996.03540150031027
  19. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-481. https://doi.org/10.1016/S0140-6736(04)15496-2
  20. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006;28:980-985. https://doi.org/10.1183/09031936.06.00125705
  21. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662. https://doi.org/10.1164/rccm.167.4.603
  22. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:653-657. https://doi.org/10.1128/AAC.47.2.653-657.2003
  23. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:2066-2069.
  24. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999;43:85-89. https://doi.org/10.1093/jac/43.suppl_1.85
  25. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122. https://doi.org/10.1128/AAC.47.10.3117-3122.2003
  26. McMurray DN. Disease model: pulmonary tuberculosis. Trends Mol Med 2001;7:135-137. https://doi.org/10.1016/S1471-4914(00)01901-8
  27. JI B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1341-1344. https://doi.org/10.1128/AAC.39.6.1341
  28. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007;51:576-582. https://doi.org/10.1128/AAC.00414-06
  29. Flynn JL, Capuano SV, Croix D, et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb) 2003;83:116-118. https://doi.org/10.1016/S1472-9792(02)00059-8
  30. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612.

Cited by

  1. New treatment options for multidrug-resistant tuberculosis vol.6, pp.5, 2012, https://doi.org/10.1177/1753465812452193
  2. Interferon‐gamma release assays versus tuberculin skin testing in patients with rheumatoid arthritis vol.16, pp.3, 2011, https://doi.org/10.1111/1756-185x.12098
  3. Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis vol.188, pp.7, 2011, https://doi.org/10.1164/rccm.201303-0604oc
  4. Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation vol.8, pp.12, 2011, https://doi.org/10.1371/journal.pone.0082943
  5. Medical Treatment of Pulmonary Multidrug-Resistant Tuberculosis vol.45, pp.4, 2011, https://doi.org/10.3947/ic.2013.45.4.367
  6. Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis vol.5, pp.1, 2015, https://doi.org/10.1186/s13336-015-0020-x
  7. Diagnosis and Treatment of Multidrug-Resistant Tuberculosis vol.88, pp.5, 2015, https://doi.org/10.3904/kjm.2015.88.5.509
  8. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB vol.71, pp.2, 2011, https://doi.org/10.1093/jac/dkv360
  9. Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients vol.60, pp.7, 2011, https://doi.org/10.1128/aac.01749-15
  10. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis vol.49, pp.3, 2011, https://doi.org/10.1183/13993003.00803-2016
  11. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach vol.13, pp.8, 2011, https://doi.org/10.1371/journal.pcbi.1005650
  12. Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13 vol.37, pp.6, 2011, https://doi.org/10.1080/07391102.2018.1462734
  13. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection vol.63, pp.7, 2011, https://doi.org/10.1128/aac.00279-19
  14. Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Multidrug Resistant Tuberculosis in Adults vol.99, pp.25, 2011, https://doi.org/10.1097/md.0000000000020648